Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Annual event brings together 1,200 plus families, physicians, researchers, caregivers, industry partners, and those living with Duchenne and Becke ...